Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands

John R. Hornick, Dirk Spitzer, Peter Goedegebuure, Robert H. MacH, William G. Hawkins

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


One major barrier in the development of pancreas cancer therapeutics is the selective delivery of the drugs to their cellular targets. We have previously developed several sigma-2 ligands and reported the discovery of a component of the receptor for these ligands. Several sigma-2 ligands have been shown to trigger apoptosis in pancreas cancer cells. More importantly, sigma-2 ligands are internalized rapidly by the cancer cells and are capable of delivering other small-molecule therapeutics. Here we review sigma-2 ligands and conjugates as a potential novel therapy suitable for investigation in patients with pancreatic cancer.

Original languageEnglish
Pages (from-to)S152-S156
JournalSurgery (United States)
Issue number3 SUPPL.
StatePublished - Sep 2012


Dive into the research topics of 'Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands'. Together they form a unique fingerprint.

Cite this